Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6289615 | 0.88 | MAPT (0.48) | DRD2DRD3DRD4NPC1RAB9A | |
| SCHEMBL6288971 | 0.83 | MAPT (0.41) | MAPK14SRCBRAFKDRNPC1 | |
| SCHEMBL6292692 | 0.81 | MAPT (0.39) | MAPK14RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL6292817 | 0.78 | LMNA (0.37) | MAPK14RAB9ASMN1; SMN2LMNAMAPT | |
| SCHEMBL6361331 | 0.76 | FABP4 (0.43) | MAPTTSHRL3MBTL1 | |
| SCHEMBL8053251 | 0.73 | DRD2 (0.70) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL1719539 | 0.71 | MAPT (0.69) | MAPK14SRCBRAFKDRNPC1 | |
| SCHEMBL21711400 | 0.67 | MAPK14 (0.56) | MAPK14SRCBRAFKDRSMN1; SMN2 | |
| SCHEMBL21185868 | 0.66 | DRD2 (0.57) | DRD2DRD3DRD4NPC1HPGD | |
| SCHEMBL13860530 | 0.66 | MAPT (0.57) | NPC1RAB9ASMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | MAPK14 1816/4885DRD2 849/4885DRD3 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.